Pirtobrutinib Demonstrates Favorable Efficacy in Patients With B-Cell Malignancies
Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Lack of Biomarker Testing in CLL/SLL May Lead to Suboptimal Treatment
More than two-thirds of patients studied did not undergo biomarker testing.
Increasing Karyotypic Complexity Linked to Poor Survival in Ibrutinib-Treated Chronic Lymphocytic Leukemia
Increasing karyotypic complexity was an independent predictor of shorter progression-free and overall survival.
Cause of Death Varies by Risk Group in Chronic Lymphocytic Leukemia
For patients with low- or intermediate-risk disease, the risk of dying from CLL progression was similar to the risk of dying from CLL-related complications or from causes unrelated to CLL.
MRD Status Not Associated With PFS in Chronic Lymphocytic Leukemia Patients on Ibrutinib
Undetectable MRD was not associated with significantly better PFS at any time point.
Acalabrutinib for Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Researchers are evaluating the safety and efficacy of acalabrutinib in 3 cohorts.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Acalabrutinib Seems Safe and Efficacious in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Venetoclax-Obinutuzumab Doesn’t Impair Quality of Life in Patients With Chronic Lymphocytic Leukemia
Quality of life outcomes were generally the same from baseline through follow-up.
Chemoimmunotherapy With Reduced Chemotherapy Exposure in CLL With Mutated IGHV and Without del(17p)/TP53 Mutation
A chemoimmunotherapy regimen with only 3 cycles of chemotherapy was found to be efficacious in a phase 2 trial that sought to reduce treatment-related MDS/AML in patients with CLL.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia
At 4 years, there was no significant difference in overall survival.
Acalabrutinib Better Tolerated Than Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia
Efficacy outcomes were similar between the treatment arms.
How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia
Experts outline treatment options for patients with venetoclax resistance.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
CLL/SLL: Ibrutinib, Venetoclax Therapy May Improve Outcomes in First Line
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
Impaired Immune Response to COVID-19 Vaccine Observed in Patients With Chronic Lymphocytic Leukemia
Patients with chronic lymphocytic leukemia had a significantly reduced antibody response rate when compared with healthy individuals.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
Loading... 
Loading...